NovaBay Pharmaceuticals Files S-1 for Stock Offering
Ticker: NBY · Form: S-1 · Filed: Jun 21, 2024 · CIK: 1389545
Sentiment: neutral
Topics: s-1, registration-statement, stock-offering, pharmaceuticals
Related Tickers: NBY
TL;DR
NovaBay (NBY) filed an S-1, get ready for potential stock dilution or a capital raise.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an S-1 registration statement on June 21, 2024, to register an unspecified amount of common stock. The company, headquartered in Emeryville, CA, is in the pharmaceutical preparations industry and is incorporated in Delaware. This filing indicates potential future stock offerings or sales by the company.
Why It Matters
This S-1 filing signals NovaBay Pharmaceuticals' intention to potentially raise capital through the sale of its stock, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which can lead to dilution for existing shareholders or indicate the company needs capital, suggesting potential financial challenges.
Key Numbers
- 333-280423 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 0001389545 — Central Index Key (Unique identifier for NovaBay Pharmaceuticals in SEC filings.)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- June 21, 2024 (date) — Filing Date
- 2000 Powell Street, Suite 1150 Emeryville, CA 94608 (address) — Principal Executive Offices
- Justin M. Hall (person) — CEO and General Counsel
- Squire Patton Boggs (US) LLP (company) — Legal Counsel
- Ellenoff Grossman & Schole LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1 filing?
The S-1 filing is a registration statement filed with the SEC to register securities for public sale, indicating NovaBay Pharmaceuticals' intent to potentially offer its common stock.
When was this S-1 filing submitted?
This S-1 filing was submitted to the SEC on June 21, 2024.
What is NovaBay Pharmaceuticals' principal business address?
NovaBay Pharmaceuticals' principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Who is the Chief Executive Officer of NovaBay Pharmaceuticals?
Justin M. Hall is the Chief Executive Officer and General Counsel of NovaBay Pharmaceuticals.
What industry does NovaBay Pharmaceuticals operate in?
NovaBay Pharmaceuticals operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Filing Stats: 4,603 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-06-21 17:26:47
Key Financial Figures
- $0 — g shares of our common stock, par value $0.01, or common stock, and Series F commo
- $2.28 — the NYSE American on June 20, 2024 was $2.28 per share. We have assumed a public off
Filing Documents
- nby20240620_s1.htm (S-1) — 575KB
- ex_690769.htm (EX-23.1) — 3KB
- ex_690770.htm (EX-FILING FEES) — 31KB
- a01.jpg (GRAPHIC) — 40KB
- a02.jpg (GRAPHIC) — 23KB
- a03.jpg (GRAPHIC) — 19KB
- logo01.jpg (GRAPHIC) — 9KB
- logo02.jpg (GRAPHIC) — 11KB
- 0001437749-24-021005.txt ( ) — 748KB
Risk Factors
Risk Factors 13 Special Note Regarding Forward-Looking Statements 25
Use of Proceeds
Use of Proceeds 26 Dividend Policy 27
Dilution
Dilution 28 Principal Stockholders 30
Description of Capital Stock
Description of Capital Stock 31
Description of Securities We Are Offering
Description of Securities We Are Offering 35
Underwriting
Underwriting 37 Legal Matters 40 Experts 40 Where You Can Find More Information 40 Incorporation of Certain Documents by Reference 40 ABOUT THIS PROSPECTUS This registration statement filed with the Securities and Exchange Commission, or the SEC, includes exhibits and documents incorporated by reference that provide more detail on the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC and the documents incorporated by reference herein before making your investment decision. You should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and the underwriter has not, authorized anyone to provide you with information or to make any representation that is in addition to, or different from, that contained or incorporated by reference in this prospectus or contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. If anyone provides you with different or inconsistent information, you should not rely on it as having been authorized by us in making a decision about whether to invest in the securities. We take no responsibility for, and cannot provide any assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, any related free writing prospectus and the documents incorporated by reference herein are accurate only as of their respective dates, regardless of the time of delivery of any such document or the time of any sale of the securities. Our business, assets, financial condition, results of operations and prospects may have changed since those dates. Therefore, you should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth